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Reported cases of Mycobacterium ulcerans disease (Buruli 
ulcer) have been increasing in southeastern Australia and 
spreading into new geographic areas. We analyzed 426 
cases of M. ulcerans disease during January 1998–May 
2017 in the established disease-endemic region of the Bel-
larine Peninsula and the emerging endemic region of the 
Mornington Peninsula. A total of 20.4% of case-patients had 
severe disease. Over time, there has been an increase in 
the number of cases managed per year and the proportion 
associated with severe disease. Risk factors associated 
with severe disease included age, time period (range of 
years of diagnosis), and location of lesions over a joint. We 
highlight the changing epidemiology and pathogenicity of M. 
ulcerans disease in Australia. Further research, including 
genomic studies of emergent strains with increased patho-
genicity, is urgently needed to improve the understanding of 
this disease to facilitate implementation of effective public 
health measures to halt its spread.
Mycobacterium ulcerans causes a necrotizing disease of skin and soft tissue known as Bairnsdale or Dain-
tree ulcer in Australia and Buruli ulcer worldwide. The 
pathogenesis of M. ulcerans is driven by production of 
mycolactone, a polyketide-derived macrolide that triggers 
apoptotic cell death (1). The clinical spectrum of M. ulcer-
ans disease ranges from usually painless nodules or ulcers 
on the limbs, to more severe forms of the disease, includ-
ing edematous lesions (2). More severe disease has major 
implications for patients in terms of increased illness and 
long-term deformities, more complicated and prolonged 
treatments, and increased treatment costs (3,4). The World 
Health Organization (WHO) classification system classi-
fies M. ulcerans disease by severity: category 1 represents 
mild disease, and categories 2 and 3 represent more severe 
disease (5). The disease is classified as a WHO neglected 
tropical disease and has become a major public health issue 
in sub-Saharan Africa and Australia.
In the state of Victoria in Australia, M. ulcerans dis-
ease was first observed in the Bairnsdale District in the 
1930s and is now established on the Bellarine Peninsula 
(6). In recent years, the epidemiology of M. ulcerans dis-
ease in southern Victoria has noticeably changed, with 
rapidly increasing numbers of human cases reported per 
year and expansion into new geographic areas, including 
the Mornington Peninsula, an adjacent area with previously 
few cases (7). The reasons for this expansion are unknown 
but might be related to changing climate, population expan-
sion, human activities, or a complex zoonotic cycle involv-
ing possums (8,9).
Clinicians from Barwon Health, a tertiary hospital in 
Geelong, Victoria, Australia, which is adjacent to the Bel-
larine Peninsula, manage a large proportion of reported 
case-patients in Victoria (10), and have recently observed 
an increasing number of severe cases of M. ulcerans dis-
ease with devastating consequences for patients. If true, 
this increase might suggest emergence of more pathogenic 
strains of M. ulcerans among other factors putting humans 
at risk. Therefore, the purpose of this study was to describe 
the epidemiology and pathogenesis of severe M. ulcerans 
disease, assess risk factors for its development, and clarify 
the evolution of severe disease in this region. Our findings 
might facilitate development of effective public health in-
terventions to reduce illness and the costs of this disease.
Methods
Case-Patient Identification
All patients with confirmed M. ulcerans disease man-
aged at Barwon Health during January 1998–May 2017 
were included in this study. A confirmed M. ulcerans case 
was defined as presence of a lesion clinically suggestive 
of M. ulcerans infection plus 1 of the following: cultur-
ing of M. ulcerans from a lesion, a positive PCR result for 
IS2404 (11) for swab or biopsy specimens from a lesion 
(performed at the Victorian Infectious Diseases Reference 
Laboratory, Melbourne, Victoria, Australia), or histopatho-
logic findings for an excised lesion showing a necrotic ul-
cer and presence of acid-fast bacilli.
Data Collection
We prospectively collected clinical and demographic data 
by using Epi Info version 6 (Centers for Disease Control 
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and Prevention, Atlanta, GA, USA). These data were in-
formation regarding age of patient; duration of symptoms 
at diagnosis; patient sex; geographic location of the case; 
concurrent conditions, such as diabetes mellitus and im-
mune suppression; and type, site, and WHO category of 
lesions. We determined lesion size by measuring the extent 
of induration associated with the lesion with a ruler.
Definitions
We defined severe disease as any lesion classified as 
WHO category 2 or 3 at diagnosis. Using WHO criteria, 
we defined category 1 lesions as single lesions <5 cm in 
diameter, category 2 lesions as single lesions 5–15 cm in 
diameter, and category 3 lesions as single lesions >15 cm 
in diameter; multiple lesions, lesions at a critical site (eye, 
breast, genitalia), or osteomyelitis (5). Plaque lesions 
were firm, painless, elevated lesions >3 cm in diameter 
with ill-defined edges. Edematous lesions were diffuse 
and usually nonpitting swelling with ill-defined margins 
involving part or all of a limb or other body part. A lesion 
over a joint was defined as a lesion overlying 1 of the 
following large joints: ankle, elbow, knee, wrist, or shoul-
der. Immune suppression was defined as current treatment 
with immunosuppressive medication (e.g., prednisolone) 
or an active malignancy. We classified cases by geograph-
ic location as acquired from either of the disease-endemic 
areas of the Bellarine or Mornington Peninsulas (Fig-
ure 1). Calendar years were categorized as time periods 
(1998–2004, 2005–2010, and 2011–2017) and included 
as a variable in analyses to assess whether time periods 
were associated with disease severity.
Statistical Analysis
We analyzed data by using SPSS version 24 (IBM, Ar-
monk, NY, USA). We compared categorical variables by 
using the Fisher exact test, χ2 test, or χ2 test for trend and 
Figure 1. Locations (circles) of 
426 cases of Mycobacterium 
ulcerans disease in Bellarine and 
Mornington Peninsulas, Barwon 
Health Cohort, Geelong, Victoria, 
Australia, January 1998–May 
2017. Size of circles indicates 
number of cases, given in 
parentheses. Box in inset  
shows study region in 
southeastern Australia.
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categorical and numerical variables by using the Indepen-
dent Student t-test, as appropriate between groups. A p 
value <0.05 indicated statistically significant differences.
We constructed a logistic regression model to assess 
the association of variables with severe disease. We ob-
tained crude odds ratios (ORs) by performing univariate 
analysis and then performed multivariable analysis for age 
and sex a priori and all other variables showing an associa-
tion with severe disease by univariate analysis (assessed 
by p<0.20): geographic location, position of lesion over 
a joint, time period (range of years of diagnosis), and dia-
betes mellitus. We determined p values for assessing the 
strength of the association of each variable with disease 
severity, which were controlled for all other variables in 
the multivariable model, by using the likelihood ratio test. 
In addition, we individually compared the association of 
severe disease at 5 body sites (ankle, elbow, hand, fore-
arm, and knee) with severe disease at all other body sites 
combined, except for these 5 sites, by using univariate lo-
gistic regression.
Ethics Approval
The study was approved by Barwon Health Human Re-
search and Ethics Committee. All data were deidentified 
before analysis.
Results
A total of 446 case-patients with M. ulcerans disease were 
managed at Barwon Health during the study period. Twen-
ty (4.5%) patients did not have WHO disease category re-
corded and were excluded. Thus, we included 426 case-
patients in the study (Figure 1). We determined the number 
of cases included per calendar year stratified by disease 
severity (Figure 2).
Baseline Characteristics
Median age for the 426 patients included in the analysis 
was 58 years (range 38–74 years), and 230 (54%) patients 
were male. Thirty-four (9.2%) cases were diagnosed dur-
ing 1998–2014, 97 (24.2%) during 2005–2010, and 295 
(66.6%) during 2011–2017. Median duration of symptoms 
before diagnosis was 42 days (interquartile range [IQR] 
28–75 days).
We determined lesion type at diagnosis: 358 (84.0%) 
of lesions were ulcers, 27 (6.3%) were nodules, 36 (8.5%) 
were edematous lesions, and 4 (0.9%) were plaques. Diag-
noses were made on the basis of a positive PCR result for 
398 (93.4%) patients, positive histopathologic results for 23 
(5.4%), and positive culture for 5 (1.2%). We determined 
that the WHO category of lesions was category 1 for 335 
(78.6%) patients, category 2 for 46 (10.8%), and category 
3 for 45 (10.6%), which resulted in 335 (78.6%) patients 
classified as having nonsevere disease and 91 (20.4%) as 
having severe disease. Lesions categorized as severe had an 
increased likelihood of being edematous (OR 19.52, 95% 
CI 8.83–43.17; p<0.001), and 21 (23.1%) of case-patients 
with severe disease had >1 lesion at presentation.
We determined sites of lesions and the proportion of 
severe disease per site (Table 1). When compared with all 
other lesions on the body combined apart from the ankle, 
elbow, forearm, hand, and knee, we found that there was a 
significantly higher likelihood of severe disease if lesions 
were located on the ankle (OR 3.99, 95% CI 2.12–7.50; 
p<0.001), elbow (OR 3.12, 95% CI 1.52–6.40; p = 0.002), 
or knee (OR 2.60, 95% CI 1.10–6.13; p = 0.029) (Table 1). 
We also identified additional baseline characteristics strati-
fied by disease severity (Table 2).
Patients with Severe Disease
Patients with severe disease were significantly older (me-
dian age 68 years, IQR 44–82 years) than patients without 
severe disease (median age 56 years, IQR 35–70 years; 
p<0.001). Univariate analysis showed that age (p = 0.004), 
geographic location (the Mornington Peninsula compared 
with the Bellarine Peninsula; p = 0.03), lesion located over 
a joint (p<0.001), time period (p = 0.01), and presence of 
diabetes mellitus (p = 0.06) were strongly associated with 
disease severity (Table 2). Univariate analysis showed that 
sex, duration of symptoms before diagnosis, and immune 
suppression were not associated with disease severity (Ta-
ble 2). Multivariate logistic regression analysis adjusting for 
age, sex, geographic location, position of lesion over a joint, 
time period, and diabetes mellitus showed that only the po-
sition of lesion over a joint (p<0.001), age (p = 0.006), and 
Figure 2. Proportion of severe and nonsevere cases of 
Mycobacterium ulcerans disease, Barwon Health Cohort, 
Geelong, Victoria, Australia, January 1998–May 2017.
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time period (p = 0.03) were significantly associated with 
severe disease (Table 2).
Discussion
The findings of our study suggest a serious change in the 
epidemiology of M. ulcerans disease in southeastern Aus-
tralia. There appears to be an increase in the proportion of 
severe cases in recent years, with a near doubling compared 
with earlier time periods to 25% of all case-patients who 
came to our health service during 2011–2017. More severe 
disease has major implications: case-patients with severe 
disease frequently require surgical treatment with tissue 
reconstruction (2) and hospitalization, and often have long-
term deformities (4). Severe disease also causes major in-
creases in cost of treatment (3). This finding is in contrast 
to nonsevere disease, which can usually be managed with 
oral antimicrobial drugs; outpatients have shown good out-
comes (12–14). We also report a large proportion of severe 
cases that affected 1 of 5 patients in our cohort. However, 
these rates are lower than those reported for cohorts in Af-
rica, in which the proportion of cases with severe disease 
(WHO categories 2 and 3 combined) was >70% (15–17). It 
has been postulated that strains in Africa are more virulent 
because of production of increased quantities and more po-
tent forms of mycolactone (18).
The reason for the increasing proportion of severe 
cases in recent years is not clear but might be related to 
evolution of a more pathogenic strain of M. ulcerans in 
the region. In the area of M. ulcerans research, utility of 
whole-genome sequencing has been studied from an eco-
logic and epidemiologic perspective. Studies indicate a 
strong relationship between the genotype of an isolate and 
the geographic origin of disease at a national and regional 
level (19–21). However, there is no information available 
on the relationship between the genotype of an isolate and 
the clinical severity of disease in affected patients. In the 
related field of M. tuberculosis research, there has been 
increasing interest in using genomic information of 
individual disease isolates to predict clinical severity of 
disease in humans (phenotype), especially for M. tuber-
culosis strains with increased drug resistance (22). We 
advocate that genomic studies be conducted to explore 
whether particular M. ulcerans strains are associated with 
more severe disease, and if strains in disease-endemic re-
gions are evolving over time to become more pathogenic. 
These studies might provide useful information for public 
health policy.
Other possible explanations for the increased propor-
tion of severe cases of M. ulcerans disease could include 
environmental or climatic changes, which lead to a higher 
inoculum of organisms. In addition, there might have been 
a change in population dynamics or characteristics that 
make humans more susceptible to severe disease (23). Al-
though human populations in disease-endemic regions are 
steadily increasing, these increases are not sufficient to ex-
plain the rapid increase in reported cases, and additional 
studies of these factors are needed.
Our analysis suggested that there was no major dif-
ference in the proportion of severe cases of M. ulcerans 
disease reported between the 2 peninsulas. This finding 
is consistent with our understanding of restricted genetic 
diversity of M. ulcerans from the same geographic loca-
tion (20,24). A recent study of isolates from 11 disease-
endemic countries in Africa identified only 2 specific M. 
ulcerans lineages; these lineages were subdivided into 4 
major clusters, and most of these isolates were in cluster 
1 (25). The spread of disease across both peninsulas in our 
study region, given their close geographic proximity, prob-
ably resulted from clonal expansion of the same genotype. 
This hypothesis is consistent with findings of a study of 
isolates from Australia in which 1 isolate from Frankston 
(Mornington Peninsula) had genomic sequences similar to 
those for isolates from Point Lonsdale and St. Leonards 
(Bellarine Peninsula) (20).
Apart from time period, we have identified 2 risk fac-
tors for severe M. ulcerans disease: a lesion situated over a 
 
Table 1. Association between lesions at body sites and proportion of persons with severe Mycobacterium ulcerans disease, Barwon 
Health Cohort, Geelong, Victoria, Australia, January 1998–May 2017* 
Site Nonsevere disease, no. (%) Severe disease, no. (%) Crude odds ratio (95% CI) p value 
Ankle 40 (62.5) 26 (37.5) 3.99 (2.12–7.50) <0.001 
Elbow 32 (68.1) 15 (31.9) 3.12 (1.52–6.40) 0.002 
Hand 16 (72.7) 6 (27.3) 2.49 (0.91–6.85) 0.077 
Forearm 18 (75.0) 6 (25.0) 2.21 (0.82–6.01) 0.118 
Knee 23 (71.9) 9 (28.1) 2.60 (1.10–6.13) 0.029 
Arm 22 (88.0) 3 (12.0) 1 ND 
Buttock 2 (66.7) 1 (33.3) 1 ND 
Foot 17 (85.0) 3 (15.0) 1 ND 
Leg 127 (86.4) 20 (13.6) 1 ND 
Head 4 (80.0) 1 (20.0) 1 ND 
Shoulder 3 (100.0) 0 1 ND 
Thigh 18 (90.0) 2 (10.0) 1 ND 
Trunk 4 (100.0) 0 1 ND 
Wrist 9 (90.0) 1 (10.0) 1 ND 
*ND, not determined. 
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joint and age. The reason for more severe disease occurring 
over joints is not clear. Reduced skin and subcutaneous tis-
sue and the absence of muscle compared with adjacent re-
gions might lead to lower tissue temperatures and increased 
growth of organisms (26,27). In addition, these factors 
might facilitate spread across tissue planes, and a reduced 
blood flow in the absence of muscle might relatively re-
duce local immune function. In contrast, increased tissue 
movement and physical stress over joints might increase 
lymph flow in the region and enhance spread of the infec-
tion, such as that hypothesized for hand, foot and mouth 
disease (28,29).
Our finding of older (>65 years) age as a risk factor 
for severe M. ulcerans disease is consistent with our previ-
ous studies that demonstrated that these patients were more 
likely to have multiple lesions or be categorized into WHO 
category 3 (30). This finding might be related to reduced 
immunity in patients in older age groups. Reduced immu-
nity inhibits control of the mycobacterium and results in 
larger, more severe forms of M. ulcerans disease, which 
is similar to immunosuppressive effects of HIV (31). Re-
duced immunity in elderly persons might also be related 
to an increased prevalence of other concurrent conditions. 
Likewise, our study findings suggest that children might be 
at increased risk for severe disease, which might be related 
to relative immune suppression in an immune system that 
is still developing.
We found that, similar to findings from Africa (32), 
more prolonged signs and symptoms before diagnosis were 
not associated with severe disease. Therefore, severe dis-
ease is not directly related to a delay in diagnosis, as is 
often believed.
With the increasing number and severity of cases of 
M. ulcerans disease in Victoria, public health measures 
to prevent the disease are needed, although these mea-
sured are hampered because the environmental reservoir 
and mode of transmission of M. ulcerans are unknown. 
Current recommendations involve mosquito and insect 
bite preventive strategies, given some evidence that mos-
quitoes or another vector might be responsible for trans-
mission (33,34). There is evidence of reduced risk for 
disease for persons outdoors in disease-endemic areas 
who reported regular use of insect repellent (35). In ad-
dition, sleeping under bed nets in Africa has been associ-
ated with a reduced incidence of disease (36). Possums 
have been postulated as a potential environmental reser-
voir in Australia (8,9), and more research is needed on 
the role of possums in the epidemiology of human M. ul-
cerans disease.
There were some limitations to this study. First, be-
cause we conducted an observational study, other unmea-
sured confounders associated with severe disease could 
affect the results. Second, there might be referral bias for 
case-patients managed at Barwon Health and increased 
 
Table 2. Logistic regression analysis of adjusted and unadjusted associations between patient characteristics and severe 
Mycobacterium ulcerans disease, Barwon Health Cohort, Geelong, Victoria, Australia, January 1998–May 2017* 
Characteristic 
Nonsevere 
disease, no. (%) 
Severe disease, 
no. (%) 
Crude odds ratio 
(95% CI) p value 
Adjusted odds ratio 
(95% CI) p value 
Age, y       
 ≤15 31 (77.5) 9 (22.5) 1.62 (0.71–3.71) 0. 004 1.73 (0.73–4.12) 0.006 
 16–64 184 (84.8) 33 (15.2) 1  1  
 ≥65 120 (71.0) 49 (29.0) 2.28 (1.38–3.75)  2.34 (1.38–3.98)  
Sex       
 F 156 (79.6) 40 (20.4) 1 0.66 1 0.51 
 M 179 (77.8) 51 (22.2) 1.11 (0.70–1.77  1.18 (0.72–1.94)  
Location       
 Mornington Peninsula 72 (70.6) 30 (29.4) 1 0.03 1 0.24 
 Bellarine Peninsula 263 (81.2) 61 (18.8) 0.56 (0.33–0.93)  0.71 (0.40–1.26)  
Lesion over a joint       
 No 228 (84.4) 42 (15.6) 1 <0.001 1 <0.001 
 Yes 107 (68.6) 49 (31.4) 2.67 (1.64–4.36)  2.71 (1.65–4.43)  
Time period       
 1998–2004 29 (85.3) 5 (14.7) 1 0.01 1 0.03 
 2005–2010 85 (87.6) 12 (12.4) 0.82 (0.27–2.52)  0.88 (0.28–2.80)  
 2011–2017 221 (74.9) 74 (25.1) 1.94 (0.73–5.20)  2.11 (0.74–5.99)  
Duration of symptoms before diagnosis, d      
 ≤75 241 (77.7) 69 (22.3) 1 0.76 NA NA 
 >75 81 (81.0) 19 (19.0) 0.82 (0.46–1.44)    
 Missing 13 (81.3) 3(18.8) 0.81 (0.22–2.91)    
Diabetes mellitus       
 No 312 (79.8) 79 (20.2) 1 0.06 1 0.14 
 Yes 23 (65.7) 12 (34.3) 2.06 (0.98–4.32)  1.86 (0.82–4.23)  
Immune suppression       
 No 310 (79.3) 81 (20.7) 1 0.31 NA NA 
 Yes 25 (71.4) 10 (28.6) 1.50 (0.69–3.27)    
*Adjusted for age, sex, location, position of lesion over a joint, time period, and diabetes mellitus. NA, not applicable. 
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numbers of severe cases referred over time because of the 
increasing expertise of clinicians in managing M. ulcerans 
disease. However, Barwon Health is the only tertiary re-
ferral center on the Bellarine Peninsula, and case-patients 
who are residents of this peninsula are seen by this health 
service regardless of disease severity. Therefore we believe 
that referral bias accounting for increasing disease severity 
over time is unlikely.
The epidemiology and pathogenicity of M. ulcerans 
disease in southeastern Australia is changing rapidly; 
we observed increases in numbers of cases per year and 
disease severity. Risk factors for severe disease include 
age, time period, and lesions located over a joint. Rea-
sons for the changing epidemiology and pathogenicity are 
unknown but these factors urgently need to be identified 
and addressed to halt spread of this increasingly devastat-
ing disease.
Dr. Tai is an infectious diseases fellow at University Hospital 
Geelong, Barwon Health, Geelong, Australia. His research  
interests are travel and tropical medicine, including the  
increasing case burden of M. ulcerans infection locally.
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